Biotech’s survival guide; What tariffs could mean for pharma; Congress pushes for $15B federal biotech investment; and more
Welcome back to Endpoints Weekly! This week's recap kicks off with Andrew Dunn's examination of the biotech playbook for surviving market turmoil. As former Alnylam CEO John Maraganore put it, recent events have "put biotech ...
